Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

J Clin Oncol. 2010 Feb 20;28(6):e91-3. doi: 10.1200/JCO.2009.25.0233. Epub 2009 Nov 23.

Authors

Elizabeth R Gerstner¹, Matthew P Frosch, Tracy T Batchelor

Affiliation

¹ Departments of Neurology and Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.

PMID: 19933906
DOI: 10.1200/JCO.2009.25.0233

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Brain Neoplasms / drug therapy
Brain Neoplasms / pathology*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Diffusion Magnetic Resonance Imaging*
Glioblastoma / drug therapy
Glioblastoma / pathology*
Humans
Irinotecan
Male
Neoplasm Recurrence, Local / diagnosis*
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Irinotecan
Camptothecin